https://insights.citeline.comFri, 10 Apr 2026 19:59:21 +0000en1hourly1premiumhttps://insights.citeline.com/medtech-insight/policy-and-regulation/recalls/medline-recalls-millions-of-angiographic-syringes-after-fda-warning-letter-GI7XZ63VIJGZRNEKFEIHBNUMPQ/https://insights.citeline.com/medtech-insight/policy-and-regulation/recalls/medline-recalls-millions-of-angiographic-syringes-after-fda-warning-letter-GI7XZ63VIJGZRNEKFEIHBNUMPQ/Fri, 10 Apr 2026 18:48:42 +0000freehttps://insights.citeline.com/pink-sheet/podcasts/pink-sheet-podcast-leucovorins-resurrection-phrmas-leadership-change-CL23NOIHVRB73FXBAJANAPYIDY/https://insights.citeline.com/pink-sheet/podcasts/pink-sheet-podcast-leucovorins-resurrection-phrmas-leadership-change-CL23NOIHVRB73FXBAJANAPYIDY/Fri, 10 Apr 2026 16:38:57 +0000premiumhttps://insights.citeline.com/medtech-insight/device-area/diagnostics/singapores-asian-population-cohort-dataset-to-move-forward-with-seers-proteograph-platform-I2SSZMVHYRGU5JHXJYBKKNZPUM/https://insights.citeline.com/medtech-insight/device-area/diagnostics/singapores-asian-population-cohort-dataset-to-move-forward-with-seers-proteograph-platform-I2SSZMVHYRGU5JHXJYBKKNZPUM/Thu, 09 Apr 2026 13:03:55 +0000premiumhttps://insights.citeline.com/medtech-insight/business/deals/boehringer-hands-ct-155-commercial-rights-to-click-therapeutics-in-50m-deal-restructure-GVU4Q75IX5FNFJ7K6MWQQDB6EY/https://insights.citeline.com/medtech-insight/business/deals/boehringer-hands-ct-155-commercial-rights-to-click-therapeutics-in-50m-deal-restructure-GVU4Q75IX5FNFJ7K6MWQQDB6EY/Fri, 10 Apr 2026 16:04:52 +0000premiumhttps://insights.citeline.com/scrip/top-12-pharma-companies-eli-lilly-shoots-to-the-top-merck-tumbles-WCGHYLQW45D4BKOEYZXBI6WAQI/https://insights.citeline.com/scrip/top-12-pharma-companies-eli-lilly-shoots-to-the-top-merck-tumbles-WCGHYLQW45D4BKOEYZXBI6WAQI/Fri, 10 Apr 2026 09:55:50 +0000premiumhttps://insights.citeline.com/generics-bulletin/business/deals/organon-rumors-persist-despite-suns-fresh-denial-YMGTFOZ4RNGNZHT6KEPR3TUMF4/https://insights.citeline.com/generics-bulletin/business/deals/organon-rumors-persist-despite-suns-fresh-denial-YMGTFOZ4RNGNZHT6KEPR3TUMF4/Fri, 10 Apr 2026 15:39:00 +0000premiumhttps://insights.citeline.com/pink-sheet/regulatory-trackers/global-pharma-guidance-update/global-pharma-guidance-tracker-march-2026-EVHY43JLLJBJ5H45ZPLJTZXAX4/https://insights.citeline.com/pink-sheet/regulatory-trackers/global-pharma-guidance-update/global-pharma-guidance-tracker-march-2026-EVHY43JLLJBJ5H45ZPLJTZXAX4/Wed, 08 Apr 2026 14:45:07 +0000premiumhttps://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/estonia-steps-into-eu-race-to-accelerate-clinical-trial-approvals-QARKPSVJ7FC5HK32R3K2M3UOHA/https://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/estonia-steps-into-eu-race-to-accelerate-clinical-trial-approvals-QARKPSVJ7FC5HK32R3K2M3UOHA/Fri, 10 Apr 2026 13:07:13 +0000premiumhttps://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-three-approvals-and-thirteen-phase-iii-readouts-H2ZZDR5GA5G75LRBNTFXTA4JD4/https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-three-approvals-and-thirteen-phase-iii-readouts-H2ZZDR5GA5G75LRBNTFXTA4JD4/Fri, 10 Apr 2026 15:06:56 +0000premiumhttps://insights.citeline.com/scrip/business/deals/roche-and-c4-expand-alliance-into-degrader-antibody-conjugate-work-JO5FLJPGYJCZPLEITAT5TLPYO4/https://insights.citeline.com/scrip/business/deals/roche-and-c4-expand-alliance-into-degrader-antibody-conjugate-work-JO5FLJPGYJCZPLEITAT5TLPYO4/Thu, 09 Apr 2026 20:59:38 +0000premiumhttps://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/real-world-evidence/canadas-hta-agency-launches-new-funding-to-strengthen-rare-disease-registries-and-rwd-ZAUDC5AUJFGDTMTWES6ZYCJWPQ/https://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/real-world-evidence/canadas-hta-agency-launches-new-funding-to-strengthen-rare-disease-registries-and-rwd-ZAUDC5AUJFGDTMTWES6ZYCJWPQ/Fri, 10 Apr 2026 13:01:22 +0000premiumhttps://insights.citeline.com/pink-sheet/market-access/pricing-debate/uk-us-trade-deal-zero-tariffs-on-uk-exports-and-possible-mfn-relief-for-uk-5DTZQQFH4BAGBJAXFFVGCYACTI/https://insights.citeline.com/pink-sheet/market-access/pricing-debate/uk-us-trade-deal-zero-tariffs-on-uk-exports-and-possible-mfn-relief-for-uk-5DTZQQFH4BAGBJAXFFVGCYACTI/Fri, 10 Apr 2026 12:45:57 +0000premiumhttps://insights.citeline.com/pink-sheet/legalandip/litigation/indias-high-stakes-oral-semaglutide-battle-and-novos-snac-wall-RUW3HFOKLJG6DM3EQ76AU7NXI4/https://insights.citeline.com/pink-sheet/legalandip/litigation/indias-high-stakes-oral-semaglutide-battle-and-novos-snac-wall-RUW3HFOKLJG6DM3EQ76AU7NXI4/Fri, 10 Apr 2026 10:56:33 +0000premiumhttps://insights.citeline.com/pink-sheet/policy-regulation/us-pharma-tariffs-exemptions-need-more-clarity-impact-varied-EJDAKYPZYNHA7FPUAYAYF3COJU/https://insights.citeline.com/pink-sheet/policy-regulation/us-pharma-tariffs-exemptions-need-more-clarity-impact-varied-EJDAKYPZYNHA7FPUAYAYF3COJU/Fri, 10 Apr 2026 09:34:14 +0000premiumhttps://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/us-fda/outlook-goes-after-fda-with-formal-dispute-resolution-request-25AKCQHFONAKTEI5KRJJZD52PQ/https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/us-fda/outlook-goes-after-fda-with-formal-dispute-resolution-request-25AKCQHFONAKTEI5KRJJZD52PQ/Fri, 10 Apr 2026 10:47:45 +0000premiumhttps://insights.citeline.com/scrip/iran-war-indias-supply-chain-shocks-contract-stress-and-spillover-risks-M7A2H6KTIZAW5MIV2YAF3AWQIQ/https://insights.citeline.com/scrip/iran-war-indias-supply-chain-shocks-contract-stress-and-spillover-risks-M7A2H6KTIZAW5MIV2YAF3AWQIQ/Fri, 10 Apr 2026 09:38:12 +0000premiumhttps://insights.citeline.com/generics-bulletin/leadership/interviews/the-number-one-priority-is-sustainable-access-aam-chair-hoffman-on-stabilizing-the-us-industry-3MSBKUFTMVCUHIPT5NYGEOQKWU/https://insights.citeline.com/generics-bulletin/leadership/interviews/the-number-one-priority-is-sustainable-access-aam-chair-hoffman-on-stabilizing-the-us-industry-3MSBKUFTMVCUHIPT5NYGEOQKWU/Fri, 10 Apr 2026 10:31:32 +0000premiumhttps://insights.citeline.com/generics-bulletin/business/deals/gtcr-takeover-fuels-zentiva-expansion-across-european-markets-3IULVACJHJBPRBLBNT6CA4CVRQ/https://insights.citeline.com/generics-bulletin/business/deals/gtcr-takeover-fuels-zentiva-expansion-across-european-markets-3IULVACJHJBPRBLBNT6CA4CVRQ/Fri, 10 Apr 2026 10:31:12 +0000premiumhttps://insights.citeline.com/scrip/therapeutic-category/anticancer/macrogenics-avoids-worst-case-scenario-for-lorigerlimab-as-us-fda-lifts-trial-hold-6INNQTNCDBGLRBUWIX5TGVS73Q/https://insights.citeline.com/scrip/therapeutic-category/anticancer/macrogenics-avoids-worst-case-scenario-for-lorigerlimab-as-us-fda-lifts-trial-hold-6INNQTNCDBGLRBUWIX5TGVS73Q/Fri, 10 Apr 2026 08:40:08 +0000premiumhttps://insights.citeline.com/scrip/focus-on-asia/japan/sumitomo-to-fortify-rd-pay-off-debt-through-730m-stock-offering-D2QYYDXGAVFWJN26KAK2XQYM3M/https://insights.citeline.com/scrip/focus-on-asia/japan/sumitomo-to-fortify-rd-pay-off-debt-through-730m-stock-offering-D2QYYDXGAVFWJN26KAK2XQYM3M/Fri, 10 Apr 2026 05:53:55 +0000premiumhttps://insights.citeline.com/medtech-insight/device-area/cardiology/no-new-hardware-required-bds-hemosphere-stream-to-bring-continuous-bp-monitoring-to-any-bedside-QONU3XSYWRGF7GVU6YGS2T43KE/https://insights.citeline.com/medtech-insight/device-area/cardiology/no-new-hardware-required-bds-hemosphere-stream-to-bring-continuous-bp-monitoring-to-any-bedside-QONU3XSYWRGF7GVU6YGS2T43KE/Wed, 08 Apr 2026 18:09:42 +0000premiumhttps://insights.citeline.com/pink-sheet/advanced-technologies/ai/china-launches-nationwide-plan-for-ai-assisted-drug-regulation-BARVROXCQFC2HBUOQFCKUF3F5A/https://insights.citeline.com/pink-sheet/advanced-technologies/ai/china-launches-nationwide-plan-for-ai-assisted-drug-regulation-BARVROXCQFC2HBUOQFCKUF3F5A/Fri, 10 Apr 2026 06:26:27 +0000premiumhttps://insights.citeline.com/pink-sheet/compliance/distribution-supply-chain/korea-on-alert-for-medical-product-shortages-amid-middle-east-crisis-AM7JU6RK2BCIDDMVXFUQNE7KNY/https://insights.citeline.com/pink-sheet/compliance/distribution-supply-chain/korea-on-alert-for-medical-product-shortages-amid-middle-east-crisis-AM7JU6RK2BCIDDMVXFUQNE7KNY/Fri, 10 Apr 2026 04:49:13 +0000premiumhttps://insights.citeline.com/scrip/drug-pricing/us-100-tariffs-loom-over-approved-chinese-innovative-drugs-GNLDG2227JCTLNCJGTZCPWXZQY/https://insights.citeline.com/scrip/drug-pricing/us-100-tariffs-loom-over-approved-chinese-innovative-drugs-GNLDG2227JCTLNCJGTZCPWXZQY/Thu, 09 Apr 2026 06:44:52 +0000freehttps://insights.citeline.com/companies/renovare-therapeuticshttps://insights.citeline.com/companies/renovare-therapeuticsFri, 10 Apr 2026 00:09:35 +0000freehttps://insights.citeline.com/companies/plateletdiagnostics-llchttps://insights.citeline.com/companies/plateletdiagnostics-llcFri, 10 Apr 2026 00:09:33 +0000freehttps://insights.citeline.com/companies/garda-therapeuticshttps://insights.citeline.com/companies/garda-therapeuticsFri, 10 Apr 2026 00:09:29 +0000freehttps://insights.citeline.com/companies/synexa-life-scienceshttps://insights.citeline.com/companies/synexa-life-sciencesFri, 10 Apr 2026 00:09:25 +0000freehttps://insights.citeline.com/companies/national-cerebral-and-cardiovascular-centerhttps://insights.citeline.com/companies/national-cerebral-and-cardiovascular-centerFri, 10 Apr 2026 00:09:21 +0000freehttps://insights.citeline.com/companies/applied-food-sciences-inchttps://insights.citeline.com/companies/applied-food-sciences-incFri, 10 Apr 2026 00:09:17 +0000freehttps://insights.citeline.com/companies/shanghai-qingrun-pharmaceutical-technology-co-ltdhttps://insights.citeline.com/companies/shanghai-qingrun-pharmaceutical-technology-co-ltdFri, 10 Apr 2026 00:09:13 +0000freehttps://insights.citeline.com/companies/hesperos-inchttps://insights.citeline.com/companies/hesperos-incFri, 10 Apr 2026 00:09:09 +0000freehttps://insights.citeline.com/companies/ahead-therapeutics-slhttps://insights.citeline.com/companies/ahead-therapeutics-slFri, 10 Apr 2026 00:09:05 +0000freehttps://insights.citeline.com/companies/beijing-demo-hi-tech-pharmaceutical-technology-co-ltdhttps://insights.citeline.com/companies/beijing-demo-hi-tech-pharmaceutical-technology-co-ltdFri, 10 Apr 2026 00:09:01 +0000freehttps://insights.citeline.com/companies/first-tracks-biotherapeutics-inchttps://insights.citeline.com/companies/first-tracks-biotherapeutics-incFri, 10 Apr 2026 00:08:57 +0000freehttps://insights.citeline.com/companies/sai-life-scienceshttps://insights.citeline.com/companies/sai-life-sciencesFri, 10 Apr 2026 00:08:53 +0000freehttps://insights.citeline.com/companies/hasten-biopharmaceuticals-sg-pte-ltdhttps://insights.citeline.com/companies/hasten-biopharmaceuticals-sg-pte-ltdFri, 10 Apr 2026 00:08:45 +0000freehttps://insights.citeline.com/companies/shanghai-record-pharmaceuticals-co-ltdhttps://insights.citeline.com/companies/shanghai-record-pharmaceuticals-co-ltdFri, 10 Apr 2026 00:08:41 +0000freehttps://insights.citeline.com/companies/cegat-gmbhhttps://insights.citeline.com/companies/cegat-gmbhFri, 10 Apr 2026 00:08:37 +0000freehttps://insights.citeline.com/companies/unc-linebergerhttps://insights.citeline.com/companies/unc-linebergerFri, 10 Apr 2026 00:08:29 +0000freehttps://insights.citeline.com/companies/nanjing-chia-tai-tianqing-pharmaceutical-co-ltdhttps://insights.citeline.com/companies/nanjing-chia-tai-tianqing-pharmaceutical-co-ltdFri, 10 Apr 2026 00:08:25 +0000freehttps://insights.citeline.com/companies/opal-bioscienceshttps://insights.citeline.com/companies/opal-biosciencesFri, 10 Apr 2026 00:08:20 +0000freehttps://insights.citeline.com/companies/inquis-medicalhttps://insights.citeline.com/companies/inquis-medicalFri, 10 Apr 2026 00:08:13 +0000freehttps://insights.citeline.com/companies/chengdu-vincentage-pharmaceutical-technology-co-ltdhttps://insights.citeline.com/companies/chengdu-vincentage-pharmaceutical-technology-co-ltdFri, 10 Apr 2026 00:08:07 +0000freehttps://insights.citeline.com/companies/rheumagen-inchttps://insights.citeline.com/companies/rheumagen-incFri, 10 Apr 2026 00:08:02 +0000freehttps://insights.citeline.com/companies/inatheryshttps://insights.citeline.com/companies/inatherysFri, 10 Apr 2026 00:07:55 +0000freehttps://insights.citeline.com/companies/bora-pharmaceuticalshttps://insights.citeline.com/companies/bora-pharmaceuticalsFri, 10 Apr 2026 00:07:49 +0000freehttps://insights.citeline.com/companies/gynicahttps://insights.citeline.com/companies/gynicaFri, 10 Apr 2026 00:07:43 +0000freehttps://insights.citeline.com/companies/oncox-biopharma-inchttps://insights.citeline.com/companies/oncox-biopharma-incFri, 10 Apr 2026 00:07:37 +0000freehttps://insights.citeline.com/companies/sathgen-therapeuticshttps://insights.citeline.com/companies/sathgen-therapeuticsFri, 10 Apr 2026 00:07:31 +0000freehttps://insights.citeline.com/companies/eikonizo-therapeuticshttps://insights.citeline.com/companies/eikonizo-therapeuticsFri, 10 Apr 2026 00:07:25 +0000freehttps://insights.citeline.com/companies/innovative-molecules-gmbhhttps://insights.citeline.com/companies/innovative-molecules-gmbhFri, 10 Apr 2026 00:07:20 +0000freehttps://insights.citeline.com/companies/oncoverity-inchttps://insights.citeline.com/companies/oncoverity-incFri, 10 Apr 2026 00:07:13 +0000freehttps://insights.citeline.com/companies/okogen-inchttps://insights.citeline.com/companies/okogen-incFri, 10 Apr 2026 00:07:07 +0000freehttps://insights.citeline.com/companies/ns-pharma-inchttps://insights.citeline.com/companies/ns-pharma-incFri, 10 Apr 2026 00:07:01 +0000freehttps://insights.citeline.com/companies/innova-vascular-inchttps://insights.citeline.com/companies/innova-vascular-incFri, 10 Apr 2026 00:06:55 +0000freehttps://insights.citeline.com/companies/meihua-international-medical-technologies-co-ltdhttps://insights.citeline.com/companies/meihua-international-medical-technologies-co-ltdFri, 10 Apr 2026 00:06:49 +0000freehttps://insights.citeline.com/companies/fascinate-therapeutics-inchttps://insights.citeline.com/companies/fascinate-therapeutics-incFri, 10 Apr 2026 00:06:43 +0000freehttps://insights.citeline.com/companies/revir-therapeuticshttps://insights.citeline.com/companies/revir-therapeuticsFri, 10 Apr 2026 00:06:37 +0000freehttps://insights.citeline.com/companies/nuvectis-pharma-inchttps://insights.citeline.com/companies/nuvectis-pharma-incFri, 10 Apr 2026 00:06:31 +0000freehttps://insights.citeline.com/companies/greywolf-therapeutics-ltdhttps://insights.citeline.com/companies/greywolf-therapeutics-ltdFri, 10 Apr 2026 00:06:25 +0000freehttps://insights.citeline.com/companies/reset-pharmaceuticals-inchttps://insights.citeline.com/companies/reset-pharmaceuticals-incFri, 10 Apr 2026 00:06:19 +0000freehttps://insights.citeline.com/companies/oncoqr-ml-gmbhhttps://insights.citeline.com/companies/oncoqr-ml-gmbhFri, 10 Apr 2026 00:06:13 +0000freehttps://insights.citeline.com/companies/oncomatryx-biopharma-slhttps://insights.citeline.com/companies/oncomatryx-biopharma-slFri, 10 Apr 2026 00:06:07 +0000freehttps://insights.citeline.com/companies/gpcr-therapeutics-inchttps://insights.citeline.com/companies/gpcr-therapeutics-incFri, 10 Apr 2026 00:06:01 +0000freehttps://insights.citeline.com/companies/medac-pharma-production-gmbhhttps://insights.citeline.com/companies/medac-pharma-production-gmbhFri, 10 Apr 2026 00:05:55 +0000freehttps://insights.citeline.com/companies/dewpoint-therapeuticshttps://insights.citeline.com/companies/dewpoint-therapeuticsFri, 10 Apr 2026 00:05:49 +0000freehttps://insights.citeline.com/companies/banner-alzheimers-institutehttps://insights.citeline.com/companies/banner-alzheimers-instituteFri, 10 Apr 2026 00:05:43 +0000freehttps://insights.citeline.com/companies/tsrl-inchttps://insights.citeline.com/companies/tsrl-incFri, 10 Apr 2026 00:05:37 +0000freehttps://insights.citeline.com/companies/life-biosciences-llchttps://insights.citeline.com/companies/life-biosciences-llcFri, 10 Apr 2026 00:05:31 +0000freehttps://insights.citeline.com/companies/mead-johnson-nutrition-cohttps://insights.citeline.com/companies/mead-johnson-nutrition-coFri, 10 Apr 2026 00:05:25 +0000freehttps://insights.citeline.com/companies/ache-laboratorios-farmaceuticos-sahttps://insights.citeline.com/companies/ache-laboratorios-farmaceuticos-saFri, 10 Apr 2026 00:05:18 +0000freehttps://insights.citeline.com/companies/imvax-inchttps://insights.citeline.com/companies/imvax-incFri, 10 Apr 2026 00:05:13 +0000freehttps://insights.citeline.com/companies/cyclarity-therapeutics-inchttps://insights.citeline.com/companies/cyclarity-therapeutics-incFri, 10 Apr 2026 00:05:07 +0000freehttps://insights.citeline.com/companies/soleno-therapeutics-inchttps://insights.citeline.com/companies/soleno-therapeutics-incFri, 10 Apr 2026 00:05:01 +0000freehttps://insights.citeline.com/companies/washington-university-school-of-medicinehttps://insights.citeline.com/companies/washington-university-school-of-medicineFri, 10 Apr 2026 00:04:54 +0000freehttps://insights.citeline.com/companies/creo-medical-ltdhttps://insights.citeline.com/companies/creo-medical-ltdFri, 10 Apr 2026 00:04:49 +0000freehttps://insights.citeline.com/companies/sydney-childrens-hospitals-networkhttps://insights.citeline.com/companies/sydney-childrens-hospitals-networkFri, 10 Apr 2026 00:04:43 +0000freehttps://insights.citeline.com/companies/shandong-buchang-pharmaceuticals-co-ltdhttps://insights.citeline.com/companies/shandong-buchang-pharmaceuticals-co-ltdFri, 10 Apr 2026 00:04:36 +0000freehttps://insights.citeline.com/companies/gl-pharmtechhttps://insights.citeline.com/companies/gl-pharmtechFri, 10 Apr 2026 00:04:30 +0000freehttps://insights.citeline.com/companies/recipharm-abhttps://insights.citeline.com/companies/recipharm-abFri, 10 Apr 2026 00:04:24 +0000freehttps://insights.citeline.com/companies/national-center-of-neurology-and-psychiatryhttps://insights.citeline.com/companies/national-center-of-neurology-and-psychiatryFri, 10 Apr 2026 00:04:18 +0000freehttps://insights.citeline.com/companies/ifm-therapeuticshttps://insights.citeline.com/companies/ifm-therapeuticsFri, 10 Apr 2026 00:04:13 +0000freehttps://insights.citeline.com/companies/hummingbird-biosciencehttps://insights.citeline.com/companies/hummingbird-bioscienceFri, 10 Apr 2026 00:04:06 +0000freehttps://insights.citeline.com/companies/c4-therapeutics-inchttps://insights.citeline.com/companies/c4-therapeutics-incFri, 10 Apr 2026 00:04:00 +0000freehttps://insights.citeline.com/companies/huadong-medicine-coltdhttps://insights.citeline.com/companies/huadong-medicine-coltdFri, 10 Apr 2026 00:03:54 +0000freehttps://insights.citeline.com/companies/imaginab-inchttps://insights.citeline.com/companies/imaginab-incFri, 10 Apr 2026 00:03:48 +0000freehttps://insights.citeline.com/companies/ideaya-biosciences-inchttps://insights.citeline.com/companies/ideaya-biosciences-incFri, 10 Apr 2026 00:03:42 +0000freehttps://insights.citeline.com/companies/everest-medicines-limitedhttps://insights.citeline.com/companies/everest-medicines-limitedFri, 10 Apr 2026 00:03:36 +0000freehttps://insights.citeline.com/companies/imunon-inchttps://insights.citeline.com/companies/imunon-incFri, 10 Apr 2026 00:03:30 +0000freehttps://insights.citeline.com/companies/gilead-sciences-inchttps://insights.citeline.com/companies/gilead-sciences-incFri, 10 Apr 2026 00:03:27 +0000freehttps://insights.citeline.com/companies/jupiter-neurosciences-inchttps://insights.citeline.com/companies/jupiter-neurosciences-incFri, 10 Apr 2026 00:03:24 +0000freehttps://insights.citeline.com/companies/trevi-therapeutics-inchttps://insights.citeline.com/companies/trevi-therapeutics-incFri, 10 Apr 2026 00:03:15 +0000freehttps://insights.citeline.com/companies/irhythm-technologies-inchttps://insights.citeline.com/companies/irhythm-technologies-incFri, 10 Apr 2026 00:03:03 +0000freehttps://insights.citeline.com/companies/nippon-shinyaku-co-ltdhttps://insights.citeline.com/companies/nippon-shinyaku-co-ltdFri, 10 Apr 2026 00:02:51 +0000freehttps://insights.citeline.com/companies/dupont-de-nemours-and-companyhttps://insights.citeline.com/companies/dupont-de-nemours-and-companyFri, 10 Apr 2026 00:02:39 +0000freehttps://insights.citeline.com/companies/proqr-therapeutics-nvhttps://insights.citeline.com/companies/proqr-therapeutics-nvFri, 10 Apr 2026 00:02:27 +0000freehttps://insights.citeline.com/companies/merck-co-inchttps://insights.citeline.com/companies/merck-co-incFri, 10 Apr 2026 00:02:03 +0000freehttps://insights.citeline.com/companies/paion-aghttps://insights.citeline.com/companies/paion-agFri, 10 Apr 2026 00:01:51 +0000freehttps://insights.citeline.com/companies/kite-pharma-inchttps://insights.citeline.com/companies/kite-pharma-incFri, 10 Apr 2026 00:00:57 +0000